Document Detail

Optimal management of severe pulmonary arterial hypertension.
MedLine Citation:
PMID:  22130818     Owner:  NLM     Status:  In-Data-Review    
Over the past decade, awareness among the medical profession of pulmonary arterial hypertension (PAH) being a treatable disease has increased. Despite this, approximately one-fifth of newly diagnosed patients are classified as being in the most severely compromised functional class (i.e. New York Health Association/World Health Organization functional class (NYHA/WHO FC) IV). The prognosis for patients in NYHA/WHO FC IV is poor, with 3-yr survival being around 40%, even with treatment. Poor prognosis coupled with severe functional impairment means it is vital that these patients receive optimal treatment. There are also subgroups of patients, who, although classified as NYHA/WHO FC III, may actually be severely haemodynamically compromised and at risk of rapid deterioration. Such subgroups include patients with PAH associated with systemic sclerosis or certain heritable mutations. These patients should be considered as being at the more severe end of the disease spectrum. In this article we will discuss the optimal management of patients with severe PAH. This includes newly emerging evidence from small-scale, open-label studies that use upfront combination therapy with intravenous epoprostenol plus oral PAH-specific drugs. We also review treatment strategies that may offer clinical benefits to patients with more severe PAH.
O Sitbon; G Simonneau
Related Documents :
438878 - Results of urinary diversion in patients with myelomeningocele.
21876428 - Neurological deficits during treatment with tumor necrosis factor-alpha antagonists.
22252798 - Population pharmacokinetics of telavancin in healthy subjects and patients with infecti...
23057958 - Hypernatremia is associated with increased risk of mortality in paediatric severe traum...
1629318 - Detection of borrelia burgdorferi dna in urine samples and cerebrospinal fluid samples ...
24383458 - Patterns of hospice use in patients dying from hematologic malignancies.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European respiratory review : an official journal of the European Respiratory Society     Volume:  20     ISSN:  1600-0617     ISO Abbreviation:  Eur Respir Rev     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111391     Medline TA:  Eur Respir Rev     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  254-61     Citation Subset:  IM    
Université Paris-Sud 11, Faculté de Médecine, Le Kremlin-Bicêtre, AP-HP, Centre de Référence de l'Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, Clamart, and INSERM U999, Hypertension Artérielle Pulmonaire, Physiopathologie et Innovation Thérapeutique, IPSIT, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of the right ventricle in pulmonary arterial hypertension.
Next Document:  Looking to the future: a new decade of pulmonary arterial hypertension therapy.